[go: up one dir, main page]

WO2011100477A3 - Anticorps et procédés de préparation de ceux-ci - Google Patents

Anticorps et procédés de préparation de ceux-ci Download PDF

Info

Publication number
WO2011100477A3
WO2011100477A3 PCT/US2011/024408 US2011024408W WO2011100477A3 WO 2011100477 A3 WO2011100477 A3 WO 2011100477A3 US 2011024408 W US2011024408 W US 2011024408W WO 2011100477 A3 WO2011100477 A3 WO 2011100477A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
antibody producing
cells
organisms
processes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/024408
Other languages
English (en)
Other versions
WO2011100477A2 (fr
Inventor
Yosef Refaeli
Brian Curtis Turner
Gregory Alan Bird
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiga Biotechnologies Inc
Original Assignee
Taiga Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiga Biotechnologies Inc filed Critical Taiga Biotechnologies Inc
Publication of WO2011100477A2 publication Critical patent/WO2011100477A2/fr
Publication of WO2011100477A3 publication Critical patent/WO2011100477A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention porte sur différents procédés de production améliorée d'organismes produisant des anticorps, de tissus produisant des anticorps, de cellules produisant des anticorps et d'anticorps. Dans certains modes de réalisation, l'invention porte sur des procédés de production rapide d'organismes, de tissus, de cellules produisant des anticorps et d'anticorps provenant d'humains, d'organismes, de plantes ou de cellules génétiquement modifiés pour amener la surexpression de certaines protéines.
PCT/US2011/024408 2010-02-10 2011-02-10 Anticorps et procédés de préparation de ceux-ci Ceased WO2011100477A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30325610P 2010-02-10 2010-02-10
US61/303,256 2010-02-10

Publications (2)

Publication Number Publication Date
WO2011100477A2 WO2011100477A2 (fr) 2011-08-18
WO2011100477A3 true WO2011100477A3 (fr) 2012-04-12

Family

ID=44368440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/024408 Ceased WO2011100477A2 (fr) 2010-02-10 2011-02-10 Anticorps et procédés de préparation de ceux-ci

Country Status (1)

Country Link
WO (1) WO2011100477A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL286053B2 (en) 2005-10-18 2023-03-01 Nat Jewish Health A process for making red blood cells using immortal hematopoietic stem cells and erythropoietin
AU2009246876B2 (en) 2008-05-16 2015-04-02 Htyr Acquisition Llc Antibodies and processes for preparing the same
ES2879225T3 (es) 2008-08-28 2021-11-22 Taiga Biotechnologies Inc Moduladores de MYC, métodos de uso de los mismos, y métodos para identificar agentes que modulan MYC
JP6141834B2 (ja) 2011-06-06 2017-06-07 ノヴォ ノルディスク アー／エス 治療抗体
ES2856179T3 (es) 2012-07-20 2021-09-27 Taiga Biotechnologies Inc Reconstitución y autorreconstitución potenciadas del compartimento hematopoyético
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
WO2015136472A1 (fr) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anticorps anti-laminine4 spécifiques contre lg4 -5
DK3116911T3 (da) 2014-03-12 2019-09-30 Prothena Biosciences Ltd Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse
CN113307858A (zh) 2016-12-02 2021-08-27 泰加生物工艺学公司 纳米颗粒调配物
WO2019027465A1 (fr) 2017-08-03 2019-02-07 Taiga Biotechnologies, Inc. Méthodes et compositions pharmaceutiques destinées au traitement du mélanome
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
AU2020272664A1 (en) 2019-04-08 2021-11-04 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
CA3137031A1 (fr) 2019-05-14 2020-11-19 Yosef Refaeli Compositions et methodes pour traiter l'epuisement des lymphocytes t
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
CN111732662B (zh) * 2020-06-11 2023-09-15 军事科学院军事医学研究院军事兽医研究所 抗H5N1病毒入胞抗体PTD-7B-mFc及其应用
AU2022207985A1 (en) 2021-01-13 2023-07-06 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062278A1 (fr) * 2002-01-25 2003-07-31 G2 Therapies Ltd Anticorps monoclonaux agissant contre des boucles extracellulaires de c5ar

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062278A1 (fr) * 2002-01-25 2003-07-31 G2 Therapies Ltd Anticorps monoclonaux agissant contre des boucles extracellulaires de c5ar
US20050244406A1 (en) * 2002-01-25 2005-11-03 Mackay Charles R Monoclonal antibodies against extracellular loops of c5ar

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GUO, R. -F. ET AL.: "C5a, a Therapeutic target in sepsis.", RECENT PATENTS IN ANTI-INFECTIVE DRUG DISCOVERY, vol. 1, January 2006 (2006-01-01), pages 57 - 65 *
LEE, H. ET AL.: "Receptor for complement C5a. The importance of C5aR and the enigmatic role of C5L2.", IMMUNOLOGY AND CELL BIOLOGY, vol. 86, no. 2, 29 January 2008 (2008-01-29), pages 153 - 160 *
OPPERMANN, M. ET AL.: "Probing the human receptor for C5a anaphylatoxic with site-directed antibodies.", JOURNAL OF IMMUNOLOGY, vol. 151, no. 7, 1 October 1993 (1993-10-01), pages 3785 - 3794 *

Also Published As

Publication number Publication date
WO2011100477A2 (fr) 2011-08-18

Similar Documents

Publication Publication Date Title
WO2011100477A3 (fr) Anticorps et procédés de préparation de ceux-ci
WO2009139930A3 (fr) Anticorps et leurs procédés de préparation
WO2011131746A3 (fr) Protéines contenant des anticorps fc hétérodimères et leurs procédés de production
WO2012097333A3 (fr) Immunoglobulines polypeptidiques à marquage aldéhydique et leur méthode d'utilisation
IL225923B (en) Cell culture material derived from a plant, methods for its preparation and uses thereof
WO2012058588A3 (fr) Nouvelles molécules se liant au récepteur egf et immunoconjugués de celles-ci
WO2009114702A3 (fr) Production recombinante de protéines humaines authentiques utilisant des systèmes d’expression de cellules humaines
WO2012019024A3 (fr) Molécules se liant à her3 et leurs immunoconjugués
WO2012094425A3 (fr) Procédés biologiques pour préparer de l'acide adipique
WO2012098537A8 (fr) Construction d'acide nucléique pour l'expression d'une alpha-galactosidase chez des plantes et des cellules végétales
HK1206756A1 (en) Modulated lysine variant species compositions and methods for producing and using the same
WO2011056644A3 (fr) Anticorps anti-glp-1r et leurs utilisations
MY181513A (en) Cell culture compositions and methods for polypeptide production
WO2013040078A3 (fr) Tissus artificiels pour des utilisations en recherche in vitro, puces de ces tissus et procédés de fabrication correspondants
HK1216894A1 (zh) 多價結合蛋白組合物
WO2013048883A3 (fr) Anticorps anti-erbb3 et leurs utilisations
WO2013029013A8 (fr) Souches de bacillus produisant une enzyme
WO2015049517A3 (fr) Modèles d'animaux et molécules thérapeutiques
WO2011062997A3 (fr) Anticorps monoclonaux humains pour nucléoline humaine
WO2010032059A3 (fr) Agents de liaison ciblés dirigés sur cd105 et leurs utilisations
WO2010068897A3 (fr) Produits protéiques renforcés par des cellules souches
MY170720A (en) Antibody formulations
WO2012054929A3 (fr) Utilisation d'albumine sérique humaine pour diminuer l'immunogénicité de protéines thérapeutiques
WO2012068317A3 (fr) Procédés de production de protéines recombinantes
WO2011091350A3 (fr) Procédés et compositions pour améliorer la production de protéines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11742823

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11742823

Country of ref document: EP

Kind code of ref document: A2